What's happening
This bill requires New York's addiction services office to support clinical research on using ibogaine to treat heroin, meth, and cocaine addiction.
Why it matters
Supports exploration of alternative addiction treatments. By mandating state support for ibogaine research, the bill could open doors to new, potentially more effective therapies for people struggling with heroin, methamphetamine, and cocaine addiction—especially for those not helped by current treatments.
State endorsement may reduce stigma and barriers. Official encouragement and resources from New York’s addiction services office could help legitimize ibogaine as a research topic, making it easier for researchers to obtain funding, institutional approval, and cooperation from medical providers.
Potential to influence broader drug policy and treatment standards. If research shows ibogaine is safe and effective, the findings could inform future policy changes, possibly leading to expanded treatment options and shifts in how addiction is managed in New York and beyond.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Support Ibogaine Drug Research
Plain English, a few words. Used as the page title.
Sponsors
Senator · Senate District 34
1 Co-sponsor
History
- Referred to alcoholism and substance use disorders
- Referred to alcoholism and substance use disorders
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Support Ibogaine Drug Research
In Assembly Committee · Alcoholism And Drug Abuse · Sponsor David Weprin
Full text
1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
6180
2023-2024 Regular Sessions
IN SENATE
April 3, 2023
Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when printed to be committed to the Committee on Alcoholism and Substance Use Disorders
AN ACT to amend the mental hygiene law, in relation to requiring the office of addiction services and supports to encourage, aid, and facilitate clinical research into the use of ibogaine in drug treatment
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Section 19.07 of the mental hygiene law is amended by adding a new subdivision (o) to read as follows:
(o) The office of addiction services and supports shall encourage, aid, and facilitate clinical research into the use of ibogaine in drug treatment for heroin, methamphetamine and cocaine addiction.
§ 2. This act shall take effect immediately.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD10569-01-3
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the mental hygiene law, in relation to requiring the office of addiction services and supports to encourage, aid, and facili- tate clinical research into the use of ibogaine in drug treatment
Purpose
To encourage and fund clinical research examining Ibogaine as a possible pharmacotherapy that would suppress the craving for cocaine, methamphe- tamine, and heroin quickly and at a lower cost than current treatment methods.
Summary of provisions
The bill amends section 19.07 of the Mental Hygiene Law and requires the Division of Substance Abuse Services to encourage, aid, and facilitate clinical research into the use of Ibogaine in drug treatment.
Rationale
Like many other states, New York has seen significant impact from the current heroin and cocaine epidemic in America. Among the most promising treatments in development is Ibogaine, a medication derived from an African botanical which has been shown to eliminate narcotic withdrawal and interrupt self-administration of drugs of abuse.
Over the past 20 years, thousands of American addicts have traveled to Mexican clinics for treatment with Ibogaine. Returning addicts report they experienced no withdrawal symptoms and that cravings to use drugs were absent. Dr. Kenneth Alper of New York University reported the emer- gence of Ibogaine as a part of a growing medical subculture. (Journal of Ethno-Pharmacology, 115: pp 924).
Justification
New York researchers have taken the lead in conducting research evaluat- ing Ibogaine. The Chairman of the Department of Pharmacology of Albany Medical College, Dr. Stanley Glick, reported that Ibogaine eliminated acute signs of opiate withdrawal in the animal model (Neuropharmacology 31: 5 pp. 497-500). He further reported that it also interrupted self- administration of morphine (European Journal of Pharmacology, 195:pp 341-345) as well as cocaine self-administration (Brain Research, 657: pp 14-22).
Dr. Henry Sershen of the Nathan Klein Institute of Psychiatric Research in Orangeburg, NY reported that Ibogaine reduces preference for cocaine consumption (Pharmacology Biochemistry and Behavior, 46:pp 942-948).
Dr. Patricia Broderick of the City University of New York MedicAl School, Department of Pharmacology, demonstrated that the effects of Ibogaine are consistent with current views regarding rational strategies for cocaine treatment. NIDA Research Monograph Series 119.
Fiscal implications
To be determined.
Legislative history
02/09/17 referred to alcoholism and drug abuse
01/03/18 referred to alcoholism and drug abuse
02/01/19 referred to alcoholism and drug abuse
01/08/20 referred to alcoholism and drug abuse
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.